comova

7 ms·

1.
by comova 1y ago
I believe this is to improve performance by shortening the context window for long thinking processes. I don't think this is referring to real-time summarizing for the users' sake.
2.
Ask HN: Could an LLM predict someone's speech 5 seconds ahead in realtime?
1 points by comova 2y ago|3 comments
3.
by comova 2y ago
For example, in the recent Phase 2b CB1 agonist for cannabis user disorder from AELIS, the FDA required a standard of efficacy of an 80% reduction in use. The trial failed for unrelated reasons, but many researchers in the field have expres
4.
by comova 2y ago
I’ve lost 60 pounds and my health has improved considerably. I was overeating out of boredom and stress. I’ve been able to reduce my blood pressure medication. My blood sugar is much more controlled. I started riding a recumbent bike for an
5.
by comova 2y ago
yes
6.
by comova 2y ago
A new, large retrospective study of patient health records shows a 40% drop in opioid overdoses and a 50% drop in cases of alcohol intoxication among people who received GLP-1RAs (typically for diabetes or obesity).
7.
by comova 2y ago
And if you haven't asked a friend who's on one, taking a GLP-1 medication reduces drinking by about 50%: https://recursiveadaptation.com/p/first-ever-randomized-tria...
8.
Drinking alcohol reduces the body's natural GLP-1 activity by 34%(recursiveadaptation.com)
51 points by comova 2y ago|22 comments
9.
by comova 2y ago
"These findings provide compelling evidence that acute alcohol consumption decreases GLP-1, a satiation signal, elucidating alcohol's 'apéritif' effect." This could increase hunger and cravings (including for more a
10.
by comova 2y ago
“I’m now offering GLP-1s to nearly all my substance use disorder patients.”
11.
by comova 2y ago
This shape, known since at least Plato's time and named by Kepler, has fascinated thinkers from Archimedes to Buckminster Fuller. As its name implies, it's somewhere between a cube and an octahedron, taking six and eight of its 1
12.
by comova 2y ago
"Because the pharma companies with approved GLP-1s do not pursue addiction treatment, a large scale trial and FDA indication will not happen on its own. Without a strategic public effort along these lines, we may be waiting 10-15 years
13.
by comova 2y ago
If you're interested in the addiction side of this, I write the substack that Scott links to in this post. Here's the article he links to: https://recursiveadaptation.com/p/the-growing-scientific-cas... I thi
14.
by comova 2y ago
GLP-1 Rapid Access Care (GRACE) is a proposed model of opioid harm reduction that would provide immediate access to GLP-1RA craving reduction treatment for people with OUD without the obstacles to initiation of opioid agonist therapy (OAT)
15.
by comova 2y ago
Smoking causes more deaths than any other substance use disorder. In the US, 480,000 people die annually from smoking-related causes. A new real-world retrospective cohort study using electronic health records from TriNetX shows a 28% reduc
16.
by comova 2y ago
We also have a history of vaccines and antibiotics, so I don't think we should automatically assume there's some deep risk. These have been on the market for over a decade now and used by tens of millions of people.
17.
by comova 2y ago
They will be coming in a few months when it gets published. They showed numbers at the conference but did not want them reported.
18.
by comova 2y ago
History of medicine is full of incredible breakthroughs that are mostly upsides, like antibiotics, vaccines, new cancer immune therapies, etc. It happens!
19.
by comova 2y ago
Hi-- this is my article! It's becoming clear that there's a revolution about to happen in addiction treatment through GLP-1s and it might be the first time we get a big positive impact on deaths from alcohol and opioids. Please
20.
First randomized trial of Ozempic for alcoholism shows big drops in drinking(recursiveadaptation.com)
83 points by comova 2y ago|81 comments
21.
The Market Failure That Will Force Doctors to Keep Writing Opioid Prescriptions(recursiveadaptation.com)
2 points by comova 2y ago|0 comments
22.
The growing scientific case for using Ozempic and other GLP-1s to stop addiction(recursiveadaptation.com)
1 points by comova 2y ago|1 comments
23.
by comova 2y ago
1. GLP-1 drugs appear to dramatically reduce addictive drive across substances. 2. GLP-1 drugs can reach vastly more patients than existing medications and they have positive mental health benefits for anxiety and depression. 3. This is our
24.
We are underfunding R&D for addiction by 95%(recursiveadaptation.com)
3 points by comova 2y ago|0 comments
25.
by comova 2y ago
hi! this is my substack post and new policy org. thanks to whoever posted this. hope you will subscribe! we are looking for folks with MDs and PhDs or other experience in the field or in EA type writing to join the project. the thesis is
26.
by comova 3y ago
can you explain more about how realistic this type of conversion actually is? has it been attempted at any level? @aimonster2
27.
by comova 3y ago
incredible concept and really well built. so many hard problems being tackled here!